Research Topics
Genomes and Genes | B W RobinsonSummaryAffiliation: University of Western Australia Country: Australia Publications
| Collaborators
|
Detail Information
Publications
Climbing Mount Kilimanjaro in a blizzardBruce W S Robinson
School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, WA
Med J Aust 181:646-8. 2004- A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependentCleo Robinson
School of Medicine and Pharmacology and Western Australian Institute for Medical Research, University of Western Australia, Perth, Australia
Cancer Res 66:10786-94. 2006..These data provide the first in vivo demonstration of co-carcinogenicity between SV40 and asbestos... - Advances in malignant mesotheliomaBruce W S Robinson
School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Nedlands, Perth, Australia
N Engl J Med 353:1591-603. 2005 - Localised spontaneous regression in mesothelioma -- possible immunological mechanismB W Robinson
University Department of Medicine, University of Western Australia, Sir Charles Gairdner Hospital, G Block, 4th Floor, Monash Avenue, 6009, Nedlands, Australia
Lung Cancer 32:197-201. 2001..The patient survived for 20 months and, in contrast to her initial biopsy, no significant lymphoid infiltrate was detected in her MM tissue at post mortem examination... - Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis--implications for tumor toleranceB W Robinson
University Department of Medicine, University of Western Australia, Nedlands, Australia
Clin Cancer Res 7:811s-817s. 2001..These data suggest that ignorance is not an explanation for the failure of the host immune system to respond to tumor antigens... - Malignant mesotheliomaBruce W S Robinson
Tumour Immunology Group, School of Medicine and Pharmacology, University of Western Australia, Australia
Lancet 366:397-408. 2005..Gene therapy and immunotherapy are used on an experimental basis only. Patterns identified from microarray studies could be useful for diagnosis as well as prognostication... - Cross-presentation of tumour antigens: evaluation of threshold, duration, distribution and regulationB W Robinson
University Department of Medicine, University of Western Australia, Queen Elizabeth II Medical Centre, Nedlands, Western Australia, Australia
Immunol Cell Biol 77:552-8. 1999..We have also used this technology to evaluate the effects of antitumour therapy on local antigen cross-presentation... - Mesothelin-family proteins and diagnosis of mesotheliomaBruce W S Robinson
University Department of Medicine, University of Western Australia, Queen Elizabeth II Medical Centre, Western Australia, Perth, Australia
Lancet 362:1612-6. 2003..Identification of such a marker would be useful in diagnosis of mesothelioma and for monitoring responses to treatment and screening at-risk individuals... - Soluble mesothelin-related protein--a blood test for mesotheliomaBruce W S Robinson
University Department of Medicine, University of Western Australia, Queen Elizabeth II Medical Centre, Perth, WA, Australia
Lung Cancer 49:S109-11. 2005..SMRP should also be useful for monitoring disease progression, and importantly, may prove useful for screening asbestos-exposed individuals for early MM... - IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2Connie Jackaman
School of Medicine and Pharmacology, University of Western Australia
J Immunol 171:5051-63. 2003..t. (but not systemic) IL-2 mediates tumor regression via an enhanced endogenous tumor-specific CTL response concomitant with reduced vasculature, thereby demonstrating a novel mechanism for IL-2 activity... - Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesotheliomaC C Leong
Australian Neuromuscular Research Institute, Queen Elizabeth II Medical Centre, Nedlands
Int J Cancer 71:476-82. 1997..Our observations are relevant to human MM because these cell lines have been derived from asbestos-induced tumors and share many properties with human cell lines of the same histological type... - The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumorS Mukherjee
Department of Medicine, University of Western Australia, Perth, Australia
Cancer Gene Ther 8:580-8. 2001..This has implications for the future design of human gene therapy trials for solid tumors such as MM... - Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapySteve A Broomfield
School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
J Immunol 182:5217-24. 2009..These results demonstrate that antitumor responses induced by locally delivered TLR7 agonists can be harnessed systemically for treating distal tumor... - Deliberately provoking local inflammation drives tumors to become their own protective vaccine siteConnie Jackaman
School of Biomedical Sciences, Curtin University, Kent St Bentley, Perth, Western Australia 6102, Australia
Int Immunol 20:1467-79. 2008..We conclude that provoking intra-tumoral inflammation skews the tumor microenvironment from tumorigenic to immunogenic, resulting in the resolution of treated and untreated distal tumors, as well long-term protective memory... - Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cellsAnna K Nowak
Tumor Immunology Group, Department of Medicine, University of Western Australia and Western Australian Institute of Medical Research, Perth, Australia
J Immunol 170:4905-13. 2003..This observation has fundamental consequences for the development of tumor immunotherapy protocols and for understanding T cell reactivity to tumors and the in vivo immune responses to apoptotic cells... - Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulationAndrew J Currie
National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
J Immunol 183:7898-908. 2009..Thus, PD-L1 blockade activates antitumor CD8 T cell most potently in the absence of CD4 T cells. These findings have implications for the development of PD-L1-based therapies... - p53 autoantibodies in patients with malignant mesothelioma: stability through disease progressionJ Creaney
Western Australian Institute for Medical Research and University Department of Medicine, University of Western Australia, Queen Elizabeth II Medical Centre, 4th Floor, G Block, Nedlands, Perth, 6009, Western Australia
Br J Cancer 84:52-6. 2001..The occurrence of anti-p53 antibodies does not serve as either a useful prognostic or diagnostic indicator in MM... - Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivoA L Marzo
The University of Western Australia Department of Medicine, Queen Elizabeth II Medical Centre, Nedlands, Perth
Cancer Res 57:3200-7. 1997..These data show that the blockade of TGF-beta2 within this tumor reduces tumor growth and raises the possibility that TGF-beta2 antisense ODNs may be useful as a therapy for this disease... - Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growthRobbert G van der Most
National Research Centre for Asbestos Related Diseases, University of Western Australia, Perth, Australia
PLoS ONE 4:e6982. 2009..Pre-clinical models clearly demonstrate that chemotherapy can synergize with immunotherapy, raising the question how the immune system can be mobilized to generate anti-tumor immune responses in the context of chemotherapy... - Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumorsAnna K Nowak
University Department of Medicine, Western Australian Institute for Medical Research, Queen Elizabeth II Medical Centre, 4th Floor, G Block, Nedlands, Perth, Western Australia 6009
Cancer Res 63:4490-6. 2003..This study provides evidence that chemotherapy has the capacity to augment cellular antitumor immunity, a finding with wider implications for the management of treatment-resistant solid tumors... - New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agentsAnna K Nowak
University Department of Medicine, University of Western Australia, Verdun St Nedlands, Australia
Semin Oncol 29:82-96. 2002..The development of more active cytotoxic combinations in this disease should facilitate further studies of chemoimmunotherapy. It seems likely that no single treatment modality will be effective by itself... - Soluble mesothelin related protein in mesotheliomaJenette Creaney
School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Wedlands, WA, Australia
J Thorac Oncol 1:172-4. 2006 - Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumorsChristine S Bundell
School of Medicine and Pharmacology, University of Western Australia, 4th Floor, G Block, Queen Elizabeth II Medical Centre, Perth, WA 6009, Australia
Cancer Immunol Immunother 55:933-47. 2006..However, intra-tumoral IL-2 treatment altered the potency, but not the hierarchy, of these CTL such that they mediated tumor regression. These results have implications for immunotherapy protocols... - Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunityRobbert G van der Most
School of Medicine and Pharmacology and Western Australian Institute for Medical Research, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Perth 6009, Australia
Cancer Res 66:601-4. 2006..We argue that this process could affect the way that a tumor works as its own cellular vaccine, and that it is differentially modulated by the choice of treatment... - Asbestos fibres inhibit the in vitro activity of lymphokine-activated killer (LAK) cells from healthy individuals and patients with malignant mesotheliomaL S Manning
University Department of Medicine, Queen Elizabeth II Medical Centre, Nedlands, Western Australia
Clin Exp Immunol 83:85-91. 1991..01). These findings suggest that asbestos exposure may suppress the function and in some instances the generation of immune effector cell mechanisms, thereby increasing the risk of disease and malignancy... - Immunotherapy and chemotherapy--a practical partnershipRichard A Lake
Tumour Immunology Group, School of Medicine and Pharmacology, Western Australian Institute for Medical Research, Perth, 6009, Australia
Nat Rev Cancer 5:397-405. 2005..These data have significant implications for the development of new protocols combining chemotherapy with immunotherapy, indicating an exciting potential for therapeutic synergy with general applicability to many cancer types... - Combined CA125 and mesothelin levels for the diagnosis of malignant mesotheliomaJenette Creaney
National Research Centre for Asbestos Related Diseases, 4th Floor, G Block, Sir Charles Gairdner Hospital, Verdun St, Nedlands, WA 6009, Australia
Chest 132:1239-46. 2007..The purpose of this study was to study the mesothelin biomarker in a large patient cohort and to determine if another biomarker, CA125, improves on the sensitivity of mesothelin in the diagnosis of mesothelioma... - Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumorsAndrew J Currie
National Research Centre for Asbestos Related Diseases, QEII Medical Centre, Verdun Street, Nedlands, Perth 6009, Western Australia
J Immunol 180:1535-44. 2008..These studies suggest that, once reactivated, pre-existing local CD8 T cell responses are sufficient to resolve established tumors and that in situ type I IFN is a determining factor... - Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesotheliomaJenette Creaney
National Research Centre for Asbestos Related Diseases, Western Australian Institute of Medical Research, School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Australia
J Thorac Oncol 3:851-7. 2008.... - Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapyRobbert G van der Most
National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
Cancer Immunol Immunother 58:1219-28. 2009..Cyclophosphamide could be used to achieve regulatory T cell depletion in combination with chemotherapy... - Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activationPhilip A Stumbles
School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia
J Immunol 173:5923-8. 2004..These data indicate that CD40 activation enhances the peripheral survival of constitutively cross-armed CTL and that persistent CD4+ T cell signals are required for their long-term activity... - Serum and pleural fluid biomarkers for mesotheliomaJenette Creaney
National Centre for Asbestos Related Diseases, Western Australian Institute of Medical Research, University of Western Australia, 4th Floor, G Block, Sir Charles Gairdner Hospital, Verdun St, Nedlands, WA 6009, Australia
Curr Opin Pulm Med 15:366-70. 2009..With the incidence of malignant mesothelioma expected to increase, it is timely to review the current status of biomarkers in this field... - CD8alpha+ DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumorAlison M McDonnell
School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia
Eur J Immunol 40:1617-27. 2010..Migratory tumor DC subsets with altered co-stimulatory receptor expression may contribute to induction and regulation of tumor-specific responses... - Serum mesothelin for early detection of asbestos-induced cancer malignant mesotheliomaJenette Creaney
National Research Centre for Asbestos Related Disease, Sir Charles Gairdner Hospital, 2School of Medicine and Pharmacology, University of Western Australia, QEII Medical Centre, Nedlands, Western Australia, Australia
Cancer Epidemiol Biomarkers Prev 19:2238-46. 2010..In this study, soluble mesothelin was determined in sequential serum samples collected from asbestos-exposed individuals before the development of mesothelioma... - Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesotheliomaJenette Creaney
Department of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Verdun Ave, Nedlands 6009, Western Australia, Australia
Thorax 62:569-76. 2007.... - Combined chemoimmunotherapy of solid tumours: improving vaccines?Anna K Nowak
Department of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, 4th Floor, G Block, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA 6009 Australia
Adv Drug Deliv Rev 58:975-90. 2006.... - Sensitivity of urinary mesothelin in patients with malignant mesotheliomaJenette Creaney
National Centre for Asbestos Related Diseases, Western Australian Institute of Medical Research, School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia
J Thorac Oncol 5:1461-6. 2010.... - Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related proteinJenette Creaney
School of Medicine and Pharmacology, University of Western Australia, 4th Floor, G Block, Sir Charles Gairdner Hospital, Nedlands 6009, Western Australia, Australia
Hematol Oncol Clin North Am 19:1025-40, v. 2005.... - Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapyH Bielefeldt-Ohmann
University of Western Australia Department of Medicine, Queen Elizabeth II Medical Centre, Nedlands
Cancer Immunol Immunother 40:241-50. 1995.... - Private specificities can dominate the humoral response to self-antigens in patients with cryptogenic fibrosing alveolitisC Robinson
University Department of Medicine, Western Australian Institute for Medical Research, Queen Elizabeth II Medical Centre, Perth, Australia
Respir Res 2:119-24. 2001..This suggests that the antibodies are epiphenomenal and are a secondary feature of tissue damage induced by some other mechanism... - Expression and integrity of DNA topoisomerase II isoforms does not explain generic drug resistance in malignant mesotheliomaB R McLaren
Western Australian Institute for Medical Research, University Department of Medicine, University of Western Australia, Perth, Australia
Cancer Chemother Pharmacol 48:1-8. 2001..CONCLUSION: We conclude that mutations in topoisomerase IIalpha can be associated with extreme resistance of mesothelioma to etoposide. The generic drug resistance of this tumour requires further investigation... - Dendritic cells infected with a vaccinia virus interleukin-2 vector secrete high levels of IL-2 and can become efficient antigen presenting cells that secrete high levels of the immunostimulatory cytokine IL-12Sutapa Mukherjee
Department of Medicine, University of Western Australia, Perth, Australia
Cancer Gene Ther 10:591-602. 2003.... - Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapySteve Broomfield
School of Medicine and Pharmacology and Western Australian Institute for Medical Research, Sir Charles Gairdner Hospital, University of Western Australia, Nedlands, Perth, Australia
Cancer Res 65:7580-4. 2005..We postulate that chemotherapy induced apoptosis of the residual tumor cells following incomplete resection is absolutely required for the induction of long-term immunologic memory... - Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapyAnna K Nowak
Western Australian Institute for Medical Research, University Department of Medicine, Queen Elizabeth II Medical Centre, 4th Floor, G Block, Nedlands, Perth, Western Australia 6009
Cancer Res 62:2353-8. 2002..In contrast, vaccination protocols requiring a humoral immune response for maximal efficacy may be compromised in patients treated with gemcitabine... - MHC multimerization, antigen expression and the induction of APC amnesia in the developing immune responseR A Lake
University Department of Medicine, Queen Elizabeth II Medical School, Nedlands, Perth, Australia
Immunol Cell Biol 77:99-104. 1999..In the present article, we propose that multimerization can result in the specific removal of ligand complexes from the cell surface of the APC, an event which may influence the overall pattern of T cell reactivity... - Intratumoral poly-N-acetyl glucosamine-based polymer matrix provokes a prolonged local inflammatory response that, when combined with IL-2, induces regression of malignant mesothelioma in a murine modelIvonne van Bruggen
University of Western Australia, School of Medicine and Pharmacology, Perth, Western Australia 6009
J Immunother (1997) 28:359-67. 2005..Hence, the IL-2/gel may provide a microenvironment that allows intratumoral T cells to proliferate and retain their cytolytic functions as they encounter their cognate antigens expressed by tumor cells... - Current chemotherapeutic treatment of malignant pleural mesotheliomaAnna K Nowak
University of Western Australia, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia
Expert Opin Pharmacother 5:2441-9. 2004..This combination has become the standard of care in mesothelioma treatment... - ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cellsJun Zhong
Department of Pharmacology, The Woolcock Institute of Medical Research, University of Sydney, New South Wales, Australia
J Cell Physiol 207:540-52. 2006..Mesothelioma progression depends on an interaction with mesothelial cells that provide MT1-MMP necessary to activate pro-MMP-2 to facilitate migration through an extracellular matrix (ECM) layer... - A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusionsAndrew J Holloway
Ian Potter Centre for Cancer Genomics and Predictive Medicine, Peter MacCallum Cancer Centre, East Melbourne, Australia
Clin Cancer Res 12:5129-35. 2006..We have therefore designed a gene expression-based test to classify the primary tumor causing a malignant pleural effusion, using cells collected from the effusion itself... - Gene therapy of mesotheliomaDelia J Nelson
Curtin University, School of Biomedical Sciences, Kent St, Bentley, Western Australia, 6102 Australia
Expert Opin Biol Ther 5:1039-49. 2005..Herein, the paper discusses past, present and future views on gene therapy in the treatment of MM...